Advancedadvanced biology

Immunology: Innate Sensing, Adaptive Memory, and Tolerance

Learning objectives

  • Contrast innate and adaptive immunity in speed, specificity, and memory.
  • Explain antigen presentation by MHC class I and II and its role in T cell activation.
  • Describe V(D)J recombination and clonal selection as the basis of receptor diversity.
  • Explain central and peripheral tolerance and how their failure causes autoimmunity.
  • Evaluate vaccine strategies and engineered immunotherapies such as CAR-T.

Innate immunity: pattern recognition and first responders

Innate immunity acts within minutes, recognizing conserved microbial features rather than specific antigens. Pattern recognition receptors are its sensors: Toll-like receptors (TLRs) stud cell surfaces and endosomes, detecting bacterial lipopolysaccharide, viral double-stranded RNA, and unmethylated CpG DNA; RIG-I and MDA5 patrol the cytosol for viral RNA; inflammasomes assemble in response to cellular damage and trigger IL-1beta release. These receptors distinguish pathogen-associated and damage-associated molecular patterns from normal self molecules -- the conceptual breakthrough of Charles Janeway. Complement proteins opsonize microbes and punch membrane pores; natural killer cells kill cells that have lost MHC class I (missing-self recognition); interferons warn neighboring cells of viral invasion. Inflammation -- redness, heat, swelling -- is this system mobilizing. Innate immunity also instructs adaptive immunity: dendritic cells carry antigen to lymph nodes and provide the co-stimulatory signals that license T cell responses, linking the two arms.

Antigen presentation: the MHC system

T cells cannot see free antigen; they inspect peptide fragments displayed by major histocompatibility complex (MHC) molecules. MHC class I, found on nearly all nucleated cells, presents peptides from proteins degraded in the cytosol by the proteasome and pumped into the endoplasmic reticulum by TAP -- a continuous report on what each cell is manufacturing, including viral proteins. CD8 cytotoxic T cells kill cells displaying foreign peptides. MHC class II, restricted to professional antigen-presenting cells (dendritic cells, macrophages, B cells), presents peptides from engulfed extracellular material to CD4 helper T cells, which then orchestrate the response. MHC genes are the most polymorphic in the human genome -- thousands of alleles -- so that populations collectively present diverse peptides; this polymorphism is also why organ transplants are rejected. The elegance of the system is its economy: a limited set of MHC molecules samples the entire proteome continuously.

Generating diversity: V(D)J recombination and clonal selection

The adaptive immune system faces an impossible numbers game: it must recognize more potential antigens than there are genes in the genome. The solution, worked out over decades, is somatic gene rearrangement. In developing lymphocytes, the RAG1/RAG2 enzymes cut and rejoin variable (V), diversity (D), and joining (J) gene segments, while terminal deoxynucleotidyl transferase adds random nucleotides at the junctions. Combinatorial plus junctional diversity yields on the order of 10^11 possible receptors from a few hundred gene segments -- a different receptor on nearly every lymphocyte. Burnet's clonal selection theory then explains the logic: each lymphocyte expresses one receptor specificity, antigen selects and expands the matching clones, and most expanded cells become short-lived effectors while a few persist as memory cells. B cells refine further in germinal centers through somatic hypermutation and class-switch recombination, evolving higher-affinity antibodies and switching from IgM to IgG, IgA, or IgE.

Tolerance: learning not to attack self

A repertoire of 10^11 random specificities inevitably includes self-reactive receptors, so tolerance mechanisms are as important as diversity generation. Central tolerance operates during lymphocyte development: in the thymus, T cells that bind self-peptide-MHC too strongly undergo negative selection (apoptosis), while the transcription factor AIRE forces thymic cells to express tissue-specific proteins -- insulin, retinal antigens -- so developing T cells are tested against the body's full molecular catalog. B cells undergo analogous selection in bone marrow. Peripheral tolerance catches escapees: anergy silences lymphocytes that see antigen without co-stimulation, and regulatory T cells expressing Foxp3 actively suppress responses. When tolerance fails, autoimmunity results -- type 1 diabetes, multiple sclerosis, lupus -- each reflecting a breach at a different checkpoint. The hygiene hypothesis proposes that reduced microbial exposure in childhood leaves these regulatory circuits undertrained, contributing to rising allergy and autoimmunity in industrialized societies, though the details remain debated.

Vaccines and engineered immunity

Vaccination exploits immunological memory: Edward Jenner's 1796 cowpox inoculation against smallpox began a practice that has saved more lives than any other medical intervention. Classical platforms include live-attenuated, inactivated, subunit, and toxoid vaccines; mRNA vaccines, proven at scale during the COVID-19 pandemic, deliver antigen-encoding instructions that the recipient's own cells translate and present, combining speed of development with strong cellular and humoral responses. Herd immunity extends protection to those who cannot be vaccinated. Monoclonal antibodies, from Kohler and Milstein's 1975 hybridoma technique (Nobel 1984), turned immune specificity into drugs for cancer, autoimmunity, and infection. The newest frontier engineers immunity itself: checkpoint inhibitors release the brakes on T cells, and CAR-T therapy grafts synthetic receptors onto a patient's T cells to hunt leukemias, producing cures in previously hopeless cases. Open challenges include a universal influenza vaccine, vaccines against highly variable pathogens like HIV, and understanding trained immunity -- the surprising memory-like behavior of innate cells -- and the microbiome's tuning of vaccine responses.

Memory is the point

Vaccines, boosters, and even allergies all reflect the same principle: the first encounter expands rare specific clones, and memory cells make the second encounter faster, stronger, and longer-lasting.

Key points

  • Innate immunity uses pattern recognition receptors (TLRs, RIG-I, inflammasomes) for immediate, broad defense.
  • MHC class I presents cytosolic peptides to CD8 T cells; MHC class II presents engulfed material to CD4 T cells.
  • V(D)J recombination by RAG enzymes generates ~10^11 receptor specificities from a few hundred gene segments.
  • Clonal selection expands antigen-matching lymphocytes; survivors become long-lived memory cells.
  • Central tolerance (thymic selection, AIRE) and peripheral tolerance (anergy, Tregs) prevent autoimmunity.
  • Vaccines, monoclonal antibodies, checkpoint inhibitors, and CAR-T all exploit adaptive immune logic.

Common misconceptions

✗ Myth: Vaccines overwhelm the immune system with too many antigens.

✓ Truth: A single natural infection exposes the immune system to far more antigens than the entire childhood vaccine schedule. Vaccines present a tiny, controlled subset -- the immune system evolved to handle vastly larger challenges daily.

✗ Myth: Innate immunity has no memory.

✓ Truth: Classically true, but the emerging concept of trained immunity shows innate cells like macrophages can mount stronger responses after certain exposures through epigenetic reprogramming. It is shorter-lived and less specific than adaptive memory, but it is real.

✗ Myth: Autoimmune diseases mean the immune system is too strong.

✓ Truth: Autoimmunity reflects failed regulation and tolerance, not excess strength. Many patients are simultaneously vulnerable to infections; the problem is misdirected specificity and broken checkpoints, which is why therapies target regulation rather than simply suppressing everything.

Frequently asked questions

Why do some vaccines need boosters?

Memory wanes at different rates for different pathogens and platforms. Boosters re-expand memory B and T cell populations and drive further affinity maturation, restoring protective antibody titers. Some vaccines, like tetanus, need decade-interval boosters; others, like measles, protect for decades after two doses.

How do mRNA vaccines actually work?

Lipid nanoparticles deliver mRNA encoding a pathogen protein into cells, which translate it and display fragments on MHC molecules while secreting the protein for B cells. This mimics a viral infection's antigen presentation without any live pathogen, generating both antibody and T cell memory.

What makes the MHC the most polymorphic human gene family?

Pathogen-driven balancing selection. Diverse MHC alleles present different peptide repertoires, so heterozygous individuals and diverse populations resist more pathogens. This same diversity causes transplant rejection when donor and recipient MHC molecules differ.

How does CAR-T therapy work?

A patient's own T cells are collected and genetically engineered to express a chimeric antigen receptor -- an antibody-derived binding domain fused to T cell signaling domains. Reinfused, they recognize cancer cells directly without needing MHC presentation, and have produced durable remissions in certain leukemias and lymphomas.